Ambrosia Biosciences, a Denver-area biotech, secured $100 million in funding to develop an oral small-molecule GLP-1 candidate in one of the most competitive metabolic markets. The financing highlights investor appetite for oral formulations that could broaden patient convenience beyond injections. The round comes as drug developers race to establish differentiated oral GLP-1 and GLP-1-adjacent products with meaningful efficacy and tolerability profiles. Ambrosia’s ability to translate oral bioavailability and sustained receptor activity into clinical benefit will be key for future trial momentum. The funding also suggests that even in mature GLP-1 categories, teams with novel chemistry and oral delivery strategies can still attract large capital commitments.